T
Treadwell Therapeutics
Developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity
About Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company that operates in the healthcare sector, specifically in the field of cancer treatment. The company is dedicated to developing innovative therapies for cancer, focusing on novel targets that have not been extensively explored in the past. Treadwell serves a market of patients who have limited treatment options, aiming to provide them with new, potentially life-changing solutions.
The company operates on a business model that involves the complete drug discovery and development process, all under one roof. This means that Treadwell is involved in every step of the process, from the initial concept and scientific research to the clinical trials and beyond. This approach allows the company to maintain control over the quality and direction of its research and development, potentially leading to more effective and innovative treatments.
Treadwell's revenue is generated primarily through the development and commercialization of its therapies. As the company advances its clinical candidates and brings them to market, it stands to earn income from the sales of these treatments. Additionally, the company may also generate revenue through partnerships with other healthcare companies or through grants and funding for its research.
In summary, Treadwell Therapeutics is a pioneering oncology company that aims to break new ground in cancer treatment. It serves a market of patients with limited options, using its in-house drug discovery and development engine to create innovative therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- New York City, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 64.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Investment activity
- 1 company, latest Oct 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2021 | $91M | $364M | 3W Fund Management · Sino Biopharmaceutical · Adrian Cheng · Alpha Win Capital | ↗ |
| SPINOUTOther financing | Mar 2020 | $0 | — | University Health Network | — |
Growth signals
Latest recorded traffic for Treadwell Therapeutics is 2.1K monthly website visits, up 23.5% over the last three months. Treadwell Therapeutics's team declined 21.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Treadwell Therapeutics in the New York City ecosystem
The Treadwell Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Sino Biopharmaceutical- 3M3W Fund Management
Adrian Cheng- ACAlpha Win Capital
TIO Bioventures- PIProsperous Alliance Investments
Other known investors1 additional known investor
University Health Network
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Treadwell Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Treadwell Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









